Get the Stockscreener App
5.14
6.20%
-0.34
Atyr Pharma Inc stock is traded at $5.14, with a volume of 2.83M.
It is down -6.20% in the last 24 hours and up +57.19% over the past month.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$5.48
Open:
$5.45
24h Volume:
2.83M
Relative Volume:
1.71
Market Cap:
$489.52M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.55%
1M Performance:
+57.19%
6M Performance:
+66.88%
1Y Performance:
+190.40%
1-Day Range:
$5.07
$5.46
1-Week Range:
$5.07
$5.7488
52-Week Range:
$1.42
$5.98
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
5.14 | 489.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
With 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backing - Yahoo Finance
Bank of America Corp DE Makes New $330,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
Cantor Fitzgerald Comments on Atyr PHARMA FY2026 Earnings - MarketBeat
Two Sigma Investments LP Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
91,224 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Bank of America Corp DE - Defense World
Atyr PHARMA (NASDAQ:ATYR) Stock Price Up 6.1%Here's Why - MarketBeat
Cantor Fitzgerald Estimates Atyr PHARMA FY2026 Earnings - Defense World
aTyr: Promising Data But Cash May Be An Issue (NASDAQ:ATYR) - Seeking Alpha
Squarepoint Ops LLC Invests $96,000 in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Two Sigma Advisers LP Makes New $44,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Millennium Management LLC Makes New Investment in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
H.C. Wainwright reaffirms aTyr Pharma stock with a $35 price target - Investing.com UK
Atyr PHARMA (NASDAQ:ATYR) Receives Buy Rating from HC Wainwright - Defense World
aTyr Pharma reports positive interim results for SSc-ILD treatment By Investing.com - Investing.com South Africa
aTyr Pharma Announces Findings from Interim Analysis of - GlobeNewswire
ATYR Stock Update: HC Wainwright Reiterates 'Buy' Rating with $3 - GuruFocus
ATYR Stock Update: HC Wainwright Reiterates 'Buy' Rating with $35 Price Target | ATYR Stock News - GuruFocus
aTyr Pharma reports positive interim results for SSc-ILD treatment - Investing.com Australia
aTyr Pharma (ATYR) Reports Promising Interim Results for Efzofitimod | ATYR Stock News - GuruFocus
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) - GlobeNewswire
Millennium Management LLC Takes $1.33 Million Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma (ATYR) Scheduled for Key Presentation in New York | - GuruFocus
aTyr Pharma (ATYR) Scheduled for Key Presentation in New York | ATYR Stock News - GuruFocus
aTyr Pharma stock soars to 52-week high of $4.66 By Investing.com - Investing.com Nigeria
Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
182,625 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Northern Trust Corp - Defense World
Woodline Partners LP Purchases New Position in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
High Growth Tech Stocks in the US to Watch This May 2025 - Yahoo Finance
Group One Trading LLC Takes $26,000 Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Jane Street Group LLC Invests $720,000 in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma’s SWOT analysis: biotech firm’s stock poised for potential breakthrough - Investing.com India
aTyr Pharma’s SWOT analysis: biotech firm’s stock poised for potential breakthrough By Investing.com - Investing.com South Africa
aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential - Insider Monkey
aTyr Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
aTyr Pharma Announces Triple Conference Schedule: RBC, Jefferies, and Piper Sandler Healthcare Events Coming Up - Stock Titan
aTyr Pharma (ATYR) Highlights Efzofitimod Research at ATS 2025 | ATYR Stock News - GuruFocus
aTyr Pharma (ATYR) Highlights Efzofitimod Research at ATS 2025 | - GuruFocus
aTyr Pharma (ATYR) Receives Steady 'Buy' Rating from HC Wainwright | ATYR Stock News - GuruFocus
Such Is The Power Of Atyr Pharma Inc (NASDAQ: ATYR) - Stocksregister
aTyr Pharma Presents Three Posters on Efzofitimod at the - GlobeNewswire
Breakthrough Phase 3 Trial Reveals 158,900 Patients Could Benefit from New Sarcoidosis Treatment - Stock Titan
Balyasny Asset Management L.P. Buys Shares of 44,310 Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference - The Manila Times
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rul - GuruFocus
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Dimensional Fund Advisors LP Makes New $881,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Atyr Pharma Inc Stock (ATYR) Financials Data
There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):